Price$6.25+1.06 (+20.52%)
2026-03-052026-06-08
News · 26 weeks21-33%
2025-12-142026-06-07
Mix1490d
- SEC Filings8(57%)
- Other6(43%)
Latest news
25 items- SECSilo Pharma Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Silo Pharma, Inc. (0001514183) (Filer)
- SECSilo Pharma Inc. filed SEC Form 8-K: Other Events8-K - Silo Pharma, Inc. (0001514183) (Filer)
- PRSilo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain InjuryNew initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma targets unmet need in a drug market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury Traumatic brain injury therapeutics market estimated to reach $6 billion by 2032 SARASOTA, FLA., May 07, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a strategic initiative to explore ibogaine-based therapeutics for the treatment of traumatic brain
- PRSilo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDFederal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today commends a wave of coordinated U.S. federal actions that are rapidly advancing the development of psychedelic-based therapeutics for mental health and substance use disorders. Building on last weekend's executive initiative to fast-track these treatments, multiple agencies have taken meaningful steps this week to accelerate research, clinical progress, and reg
- PRSilo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon PsychedelicsSPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today highlighted the strength and strategic positioning of its pipeline in response to increasing national attention and policy discussion surrounding psychedelic-based treatments for mental health disorders. Recent national media coverage has underscored growing momentum at the federal level to evaluate reforms related to psychedelic compounds for medical use—particularly in areas such as post-traumat
- SECSEC Form 424B3 filed by Silo Pharma Inc.424B3 - Silo Pharma, Inc. (0001514183) (Filer)
- SECSEC Form EFFECT filed by Silo Pharma Inc.EFFECT - Silo Pharma, Inc. (0001514183) (Filer)
- SECSEC Form 424B3 filed by Silo Pharma Inc.424B3 - Silo Pharma, Inc. (0001514183) (Filer)
- SECSEC Form POS AM filed by Silo Pharma Inc.POS AM - Silo Pharma, Inc. (0001514183) (Filer)
- SECSEC Form EFFECT filed by Silo Pharma Inc.EFFECT - Silo Pharma, Inc. (0001514183) (Filer)
- SECSEC Form POS AM filed by Silo Pharma Inc.POS AM - Silo Pharma, Inc. (0001514183) (Filer)
- PRSilo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention TherapyEPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress" (European Patent Application No. 20786878.7) that
- SECSilo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Silo Pharma, Inc. (0001514183) (Filer)
- SECSEC Form 10-K filed by Silo Pharma Inc.10-K - Silo Pharma, Inc. (0001514183) (Filer)
- SECSilo Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Silo Pharma, Inc. (0001514183) (Filer)
- PRSilo Pharma Announces Share Buyback ProgramSarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. The Company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as repo
- PRSilo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property PortfolioSARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traumatic Stress Disorder (PTSD). The allowed application, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," strengthens Silo's growing intellectual-proper
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Silo Pharma Inc.SCHEDULE 13G/A - Silo Pharma, Inc. (0001514183) (Subject)
- PRSilo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a non-binding Letter of Intent ("LOI") with Allucent (US) LLC ("Allucent"), a global clinical research organization (CRO), to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subject
- SECSilo Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Silo Pharma, Inc. (0001514183) (Filer)
- INSIDERChief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)4 - Silo Pharma, Inc. (0001514183) (Issuer)
- SECSEC Form EFFECT filed by Silo Pharma Inc.EFFECT - Silo Pharma, Inc. (0001514183) (Filer)
- SECSEC Form 424B3 filed by Silo Pharma Inc.424B3 - Silo Pharma, Inc. (0001514183) (Filer)
- INSIDERChief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)4 - Silo Pharma, Inc. (0001514183) (Issuer)
- INSIDERChief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)4 - Silo Pharma, Inc. (0001514183) (Issuer)
SILO FAQ
4 questionsWhere does SILO stock trade?
Silo Pharma Inc. (SILO) is listed on NASDAQ.What sector and industry is SILO in?
Silo Pharma Inc. operates in the Consumer Discretionary sector, Apparel industry.What companies are similar to SILO?
Notable peers in the same industry include TPR (Tapestry Inc.), AS (Amer Sports Inc.), LULU (lululemon athletica inc.), GIL (Gildan Activewear Inc.), LEVI (Levi Strauss & Co). Compare SILO side-by-side with any of them on Quantisnow.How can I track SILO on Quantisnow?
Quantisnow aggregates Silo Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SILO to receive live email and push alerts on every new disclosure.